Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 1, 2008, Pages 146-156

  Staib, Peter ^a,b   Lermann, Ulrich ^a   Blaß Warmuth, Julia ^a   Degel, Björn ^a   Würzner, Reinhard ^c   Monod, Michel ^b   Schirmeister, Tanja ^a   Morschhäuser, Joachim ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; BOVINE SERUM ALBUMIN; ISOENZYME; NITROGEN; PEPSTATIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SECRETED ASPARTIC PROTEASE 1P; SECRETED ASPARTIC PROTEASE 2P; SECRETED ASPARTIC PROTEASE 3P; SECRETED ASPARTIC PROTEASE 4P; SECRETED ASPARTIC PROTEASE 5P; SECRETED ASPARTIC PROTEASE 6P; SECRETED ASPARTIC PROTEASE 8P; SECRETED ASPARTIC PROTEASE 9P; TETRACYCLINE; UNCLASSIFIED DRUG;

ARTICLE; BIOASSAY; CANDIDA ALBICANS; CULTURE MEDIUM; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; FUNGAL GENE; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS CULTURE; FUNGUS GROWTH; GROWTH INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SAP GENE; SAP2 GENE;

ASPARTIC ENDOPEPTIDASES; CANDIDA ALBICANS; CULTURE MEDIA; ENZYME INDUCTION; HUMANS; ISOENZYMES; MICROBIAL SENSITIVITY TESTS; MUTATION; PEPSTATINS; PROMOTER REGIONS (GENETICS); PROTEASE INHIBITORS; RITONAVIR; SAQUINAVIR; TETRACYCLINE;

EID: 37849041277     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01072-07     Document Type: Article

References (56)

1. Albrecht, A., A. Felk, I. Pichova, J. R. Naglik, M. Schaller, P. de Groot, D. Maccallum, F. C. Odds, W. Schafer, F. Klis, M. Monod, and B. Hube. 2006. Glycosylphosphatidylinositol-anchored proteases of Candida albicans target proteins necessary for both cellular processes and host-pathogen interactions. J. Biol. Chem. 281:688-694.
2. Backman, D., M. Monod, and U. H. Danielson. 2006. Biosensor-based screening and characterization of HIV-1 inhibitor interactions with Sap 1, Sap 2, and Sap 3 from Candida albicans. J. Biomol. Screen. 11:165-175.
3. Bektić, J., C. P. Lell, A. Fuchs, H. Stoiber, C. Speth, C. Lass-Florl, M. Borg-von Zepelin, M. P. Dierich, and R. Wurzner. 2001. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. FEMS Immunol. Med. Microbiol. 31:65-71.
4. Biswas, K., and J. Morschhäuser. 2005. The Mep2p ammonium permease controls nitrogen starvation-induced filamentous growth in Candida albicans. Mol. Microbiol. 56:649-669.
5. Blanco, M. T., C. Hurtado, C. Perez-Giraldo, F. J. Moran, C. Gonzalez-Velasco, and A. C. Gomez-Garcia. 2003. Effect of ritonavir and saquinavir on Candida albicans growth rate and in vitro activity of aspartyl proteinases. Med. Mycol. 41:167-170.
6. Borg-von Zepelin, M., S. Beggah, K. Boggian, D. Sanglard, and M. Monod. 1998. The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages. Mol. Microbiol. 28:543-554.
7. Borg-von Zepelin, M., I. Meyer, R. Thomssen, R. Wurzner, D. Sanglard, A. Telenti, and M. Monod. 1999. HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J. Investig. Dermatol. 113:747-751.
8. Boucher, H. W., A. H. Groll, C. C. Chiou, and T. J. Walsh. 2004. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 64: 1997-2020.
9. Cassone, A., F. De Bernardis, A. Torosantucci, E. Tacconelli, M. Tumbarello, and R. Cauda. 1999. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J. Infect. Dis. 180:448-453.
10. Cauda, R., E. Tacconelli, M. Tumbarello, G. Morace, F. De Bernardis, A. Torosantucci, and A. Cassone. 1999. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J. Acquir. Immune Defic. Syndr. 21:20-25.
11. Cawley, N. X., M. Chino, A. Maldonado, Y. M. Rodriguez, Y. P. Loh, and J. A. Ellman. 2003. Synthesis and characterization of the first potent inhibitor of yapsin 1. Implications for the study of yapsin-like enzymes. J. Biol. Chem. 278:5523-5530.
12. Colina, A. R., F. Aumont, N. Deslauriers, P. Belhumeur, and L. de Repentigny. 1996. Evidence for degradation of gastrointestinal mucin by Candida albicans secretory aspartyl proteinase. Infect. Immun. 64:4514-4519.
13. De Bernardis, F., M. Boccanera, D. Adriani, E. Spreghini, G. Santoni, and A. Cassone. 1997. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect. Immun. 65:3399-3405.
14. De Groot, P. W., K. J. Hellingwerf, and F. M. Klis. 2003. Genome-wide identification of fungal GPI proteins. Yeast 20:781-796.
15. Dostál, J., P. Hamal, L. Pavlickova, M. Soucek, T. Ruml, I. Pichova, and O. Hruskova-Heidingsfeldova. 2003. Simple method for screening Candida species isolates for the presence of secreted proteinases: a tool for the prediction of successful inhibitory treatment. J. Clin. Microbiol. 41:712-716.
16. Edison, A. M., and M. Manning-Zweerink. 1988. Comparison of the extracellular proteinase activity produced by a low-virulence mutant of Candida albicans and its wild-type parent. Infect. Immun. 56:1388-1390.
17. Eisenhaber, B., G. Schneider, M. Wildpaner, and F. Eisenhaber. 2004. A sensitive predictor for potential GPI lipid modification sites in fungal protein sequences and its application to genome-wide studies for Aspergillus nidulans, Candida albicans, Neurospora crassa, Saccharomyces cerevisiae and Schizosaccharomyces pombe. J. Mol. Biol. 337:243-253.
18. Fallon, K., K. Bausch, J. Noonan, E. Huguenel, and P. Tamburini. 1997. Role of aspartic proteases in disseminated Candida albicans infection in mice. Infect. Immun. 65:551-556.
19. Gillum, A. M., E. Y. Tsay, and D. R. Kirsch. 1984. Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol. Gen. Genet. 198:179-182.
20. Gruber, A., C. Speth, E. Lukasser-Vogl, R. Zangerle, M. Borg-von Zepelin, M. P. Dierich, and R. Wurzner. 1999. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 41:227-234.
21. Hoegl, L., E. Thoma-Greber, M. Rocken, and H. C. Korting. 1998. HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study. Mycoses 41:321-325.
22. Hube, B., M. Monod, D. A. Schofield, A. J. Brown, and N. A. Gow. 1994. Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans. Mol. Microbiol. 14:87-99.
23. Hube, B., D. Sanglard, F. C. Odds, D. Hess, M. Monod, W. Schafer, A. J. Brown, and N. A. Gow. 1997. Disruption of each of the secreted aspartyl proteinase genes SAP1, SAP2, and SAP3 of Candida albicans attenuates virulence. Infect. Immun. 65:3529-3538.
24. Koelsch, G., J. Tang, J. A. Loy, M. Monod, K. Jackson, S. I. Foundling, and X. Lin. 2000. Enzymic characteristics of secreted aspartic proteases of Candida albicans. Biochim. Biophys. Acta 1480:117-131.
25. Köhler, G. A., T. C. White, and N. Agabian. 1997. Overexpression of a cloned IMP dehydrogenase gene of Candida albicans confers resistance to the specific inhibitor mycophenolic acid. J. Bacteriol. 179:2331-2338.
26. Korting, H. C., M. Schaller, G. Eder, G. Hamm, U. Bohmer, and B. Hube. 1999. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob. Agents Chemother. 43:2038-2042.
27. Kretschmar, M., B. Hube, T. Bertsch, D. Sanglard, R. Merker, M. Schroder, H. Hof, and T. Nichterlein. 1999. Germ tubes and proteinase activity contribute to virulence of Candida albicans in murine peritonitis. Infect. Immun. 67:6637-6642.
28. Millon, L., A. Manteaux, G. Reboux, C. Drobacheff, M. Monod, T. Barale, and Y. Michel-Briand. 1994. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J. Clin. Microbiol. 32:1115-1118.
29. Monod, M., M. Borg-von Zepelin, A. Telenti, and D. Sanglard. 1999. The inhibition of Candida-albicans-secreted aspartic proteases by three different HIV protease inhibitors. Dermatology 198:412-414.
30. Monod, M., B. Hube, D. Hess, and D. Sanglard. 1998. Differential regulation of SAP8 and SAP9, which encode two new members of the secreted aspartic proteinase family in Candida albicans. Microbiology 144(Pt. 10):2731-2737.
31. Monod, M., G. Togni, B. Hube, and D. Sanglard. 1994. Multiplicity of genes encoding secreted aspartic proteinases in Candida species. Mol. Microbiol. 13:357-368.
32. Morschhäuser, J., R. Virkola, T. K. Korhonen, and J. Hacker. 1997. Degradation of human subendothelial extracellular matrix by proteinase-secreting Candida albicans. FEMS Microbiol. Lett. 153:349-355.
33. Naglik, J. R., S. J. Challacombe, and B. Hube. 2003. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol. Mol. Biol. Rev. 67:400-428.
34. Naglik, J. R., G. Newport, T. C. White, L. L. Fernandes-Naglik, J. S. Greenspan, D. Greenspan, S. P. Sweet, S. J. Challacombe, and N. Agabian. 1999. In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis. Infect. Immun. 67:2482-2490.
35. Odds, F. C. 1988. Candida and candidosis: a review and bibliography. Bailliere Tindall, London, United Kingdom.
36. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338:853-860.
37. Park, Y. N., and J. Morschhäuser. 2005. Tetracycline- inducible gene expression and gene deletion in Candida albicans. Eukaryot. Cell 4:1328-1342.
38. Perfect, J. R. 1996. Fungal virulence genes as targets for antifungal chemotherapy. Antimicrob. Agents Chemother. 40:1577-1583.
39. Pichova, I., L. Pavlickova, J. Dostal, E. Dolejsi, O. Hruskova-Heidingsfeldova, J. Weber, T. Ruml, and M. Soucek. 2001. Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors. Eur. J. Biochem. 268: 2669-2677.
40. Reuß, O., Å. Vik, R. Kolter, and J. Morschhäuser. 2004. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. Gene 341:119-127.
41. Rüchel, R. 1981. Properties of a purified proteinase from the yeast Candida albicans. Biochim. Biophys. Acta 659:99-113.
42. Rüchel, R., B. Ritter, and M. Schaffrinski. 1990. Modulation of experimental systemic murine candidosis by intravenous pepstatin. Zentralbl. Bakteriol. 273:391-403.
43. Schaller, M., B. Hube, M. W. Ollert, W. Schafer, M. Borg-von Zepelin, E. Thoma-Greber, and H. C. Korting. 1999. In vivo expression and localization of Candida albicans secreted aspartyl proteinases during oral candidiasis in HIV-infected patients. J. Investig. Dermatol. 112:383-386.
44. Skrbec, D., and D. Romeo. 2002. Inhibition of Candida albicans secreted aspartic protease by a novel series of peptidomimetics, also active on the HIV-1 protease. Biochem. Biophys. Res. Commun. 297:1350-1353.
45. Smolenski, G., P. A. Sullivan, S. M. Cutfield, and J. F. Cutfield. 1997. Analysis of secreted aspartic proteinases from Candida albicans: purification and characterization of individual Sap1, Sap2 and Sap3 isoenzymes. Microbiology 143(Pt. 2):349-356.
46. Staib, F. 1965. Serum-proteins as nitrogen source for yeastlike fungi. Sabouraudia 4:187-193.
47. Staib, P., M. Kretschmar, T. Nichterlein, H. Hof, and J. Morschhäuser. 2000. Differential activation of a Candida albicans virulence gene family during infection. Proc. Natl. Acad. Sci. USA 97:6102-6107.
48. Staib, P., M. Kretschmar, T. Nichterlein, H. Hof, and J. Morschhäuser. 2002. Host versus in vitro signals and intrastrain allelic differences in the expression of a Candida albicans virulence gene. Mol. Microbiol. 44:1351-1366.
49. Stewart, K., and C. Abad-Zapatero. 2001. Candida proteases and their inhibition: prospects for antifungal therapy. Curr. Med. Chem. 8:941-948.
50. Tossi, A., F. Benedetti, S. Norbedo, D. Skrbec, F. Berti, and D. Romeo. 2003. Small hydroxyethylene-based peptidomimetics inhibiting both HIV-1 and C. albicans aspartic proteases. Bioorg. Med. Chem. 11:4719-4727.
51. Umezawa, H., T. Aoyagi, H. Morishima, M. Matsuzaki, and M. Hamada. 1970. Pepstatin, a new pepsin inhibitor produced by Actinomycetes. J. Antibiot. (Tokyo) 23:259-262.
52. Watts, H. J., F. S. Cheah, B. Hube, D. Sanglard, and N. A. Gow. 1998. Altered adherence in strains of Candida albicans harbouring null mutations in secreted aspartic proteinase genes. FEMS Microbiol. Lett. 159:129-135.
53. White, T. C., and N. Agabian. 1995. Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors. J. Bacteriol. 177:5215-5221.
54. Zhang, Z., H. N. ElSohly, M. R. Jacob, D. S. Pasco, L. A. Walker, and A. M. Clark. 2002. Natural products inhibiting Candida albicans secreted aspartic proteases from Tovomita krukovii. Planta Med. 68:49-54.
55. Zingman, B. S. 1996. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N. Engl. J. Med. 334: 1674-1675.
56. Zotter, C., U. F. Haustein, C. Schonborn, H. D. Grimmecke, and H. Wand. 1990. Effect of pepstatin A on Candida albicans infection in the mouse. Dermatol. Monatsschr. 176:189-198.